Ovid Therapeutics
OVID
55 hedge funds and large institutions have $74.5M invested in Ovid Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 14 closing their positions.
0.75% less ownership
Funds ownership: 49.92% → 49.18% (-0.75%)
11% less funds holding
Funds holding: 62 → 55 (-7)
33% less capital invested
Capital invested by funds: $110M → $74.5M (-$35.9M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
50% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 24
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$6.97M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.38M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.49M |
| 4 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$166K |
| 5 |
Renaissance Technologies
New York
|
+$94.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Globeflex Capital
San Diego,
California
|
-$4.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.79M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.76M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.72M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$744K |
OVID Hedge Fund Activity: Q2 2022 in Review
55 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2022, worth a combined $74.5M — down 33% from $110M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of OVID and 7 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 12 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $6.97M. The largest seller was Globeflex Capital, exiting entirely with an estimated $4.1M sold.
- 55 institutional investors held Ovid Therapeutics (OVID) as of Q2 2022, down from 62 in Q1 2022.
- Funds reported $74.5M of Ovid Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
- 7 funds opened new Ovid Therapeutics positions in Q2 2022 and 14 closed out, a net change of -7 holders.
- The largest Ovid Therapeutics buyer in Q2 2022 was Rubric Capital Management (New York), an estimated $6.97M added.
- The largest Ovid Therapeutics seller in Q2 2022 was Globeflex Capital, an estimated $4.1M sold.
Based on aggregated 13F filings for Q2 2022.